Bayer (FRA:BAYN) has been given a €85.00 ($98.84) price objective by research analysts at Independent Research in a research report issued to clients and investors on Wednesday. The brokerage currently has a “neutral” rating on the healthcare company’s stock. Independent Research’s target price would indicate a potential upside of 13.50% from the stock’s current price.
BAYN has been the subject of several other reports. Sanford C. Bernstein set a €115.00 ($133.72) target price on shares of Bayer and gave the stock a “buy” rating in a research report on Monday, August 20th. Jefferies Financial Group set a €92.00 ($106.98) target price on shares of Bayer and gave the stock a “neutral” rating in a research report on Wednesday, August 15th. Citigroup set a €93.00 ($108.14) target price on shares of Bayer and gave the stock a “neutral” rating in a research report on Tuesday, August 14th. Goldman Sachs Group set a €116.00 ($134.88) price objective on shares of Bayer and gave the stock a “buy” rating in a research report on Wednesday. Finally, HSBC set a €82.00 ($95.35) price objective on shares of Bayer and gave the stock a “neutral” rating in a research report on Monday, August 20th. Nine equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of €104.05 ($120.98).
FRA:BAYN opened at €74.89 ($87.08) on Wednesday. Bayer has a one year low of €91.58 ($106.49) and a one year high of €123.82 ($143.98).
Bayer Company Profile
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Read More: What is a Leveraged Buyout (LBO)?
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.